Citations

Showing 10 of 108094 citations.

Biologics: how far can they go in Crohn’s disease?
Dunleavy, Katie A. , Pardi, Darrell S. , Dunleavy, Katie

Mayo Clinic

Gastroenterology Report | September 29, 2022 | Volume: 10 | Issue: No issue available | Pages: No page available

10.1093/gastro/goac049 | PMID 36196255 Get It

Abstract Crohn’s disease is a chronic gastrointestinal inflammatory disorder, characterized by episodes of relapsing and remitting flares. As the disease mechanism becomes better elucidated, there is a significant increase in the number of available biologic therapies. This article summarizes and synthesizes current Food and Drug Administration-approved biological therapy for Crohn’s disease and examines the positioning of medical therapy as emerging biologics break onto the market.
Incidence of Status Migrainosus in Olmsted County, Minnesota, United States
VanderPluym, Juliana H. , Mangipudi, Kartik, Mbonde, Amir Abdallah, Gritsch, David , Butterfield, Richard , Mbonde, Amir A. , Caronna, Edoardo , VanderPluym, Juliana , Singh, Rashmi B. Halker , Smith, Jonathan H.

Mayo Clinic

Neurology | September 29, 2022 | Volume: 100 | Issue: 3 | Pages: No page available

10.1212/wnl.0000000000201382 | PMID 36175145 Get It

Epidemiology and Outcomes of Hypertension
Taler, Sandra J.

Mayo Clinic

Nephrology Self-Assessment Program | September 29, 2022 | Volume: 21 | Issue: 4 | Pages: 269-275

10.1681/nsap.00052022 Get It

Renal Transplant Rejection and Tolerance
Schinstock, Carrie A. , Bentall, Andrew

Mayo Clinic

Nephrology Self-Assessment Program | September 29, 2022 | Volume: 21 | Issue: 3 | Pages: 199-210

10.1681/nsap.00302022 Get It

Durable biochemical response and safety with oral octreotide capsules in acromegaly
Samson, Susan L. , Nachtigall, Lisa B. , Fleseriu, Maria , Manning, Patrick , Molitch, Mark E. , Patou, Gary, Haviv, Asi, Giustina, Andrea , Strasburger, Christian J. , Kennedy, Laurence, Мелмед, Шломо , Jensterle, Mojca , Elenkova, Atanaska P. , Ludlam, W.H. , Biermasz, Nienke Ruurdje , Fleseriu, Maria

Mayo Clinic

European Journal of Endocrinology | September 29, 2022 | Volume: 187 | Issue: 6 | Pages: 733-741

10.1530/eje-22-0220 | PMID 36173649 Get It

Abstract Objective The objective of this study is to report results from the open-label extension (OLE) of the OPTIMAL trial of oral octreotide capsules (OOC) in adults with acromegaly, evaluating the long-term durability of therapeutic response. Design The study design is an OLE of a double-blind placebo-controlled (DPC) trial. Methods Patients completing the 36-week DPC period on the study drug (OOC or placebo) or meeting predefined withdrawal criteria were eligible for OLE enrollment at 60 mg/day OOC dose, with the option to titrate to 40 or 80 mg/day. The OLE is ongoing; week 48 results are reported. Results Forty patients were enrolled in the OLE, 20 each having received OOC or placebo, with 14 and 5 patients completing the DPC period as responders, respectively. Ninety percent of patients completing the DPC period on OOC and 70% of those completing on placebo completed 48 weeks of the OLE. Maintenance of response in the OLE (i.e. insulin-like growth factor I (IGF1) ≤ 1.0 × upper limit of normal (ULN)) was achieved by 92.6% of patients who responded to OOC during the DPC period. Mean IGF1 levels were maintained between the end of the DPC period (0.91 × ULN; 95% CI: 0.784, 1.045) and week 48 of the OLE (0.90 × ULN; 95% CI: 0.750, 1.044) for those completing the DPC period on OOC. OOC safety was consistent with previous findings, with no increased adverse events (AEs) associated with the higher dose and improved gastrointestinal tolerability observed over time. Conclusions Patients with acromegaly maintained long-term biochemical response while receiving OOC, with no new AEs observed with prolonged OOC exposure.
Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive disease
Roofeh, David , Brown, Kevin M. , Kazerooni, Ella A. , Tashkin, Donald P. , Assassi, Shervin , Martínez, Fernando J. , Wells, Athol U. , Raghu, Ganesh , Denton, Christopher P. , Chung, Leland W.K. , Matteson, Eric L. , Pauling, John D , Seibold, James R. , Volkmann, Elizabeth R. , Walsh, Simon , White, Eric S. , Barratt, Shaney , Domsic, Robyn T. , Dellaripa, Paul F. , Rosas, Iván O. , Bhatt, Nitin, Hsu, Vivien , Kahaleh, Bashar , Garcha, Puneet , Khanna, Surabhi , Lin, Celia J. F., Mathai, Stephen C. , Doyle, Tracy J. , Steen, Virginia , Zoz, Donald F., Rodríguez‐Pintó, Ignasi , Lewandoski, Andrew, Belloli, Elizabeth A. , Lescoat, Alain , Nagaraja, Vivek , Ye, Wen , Huang, Suiyuan, Maher, Toby M. , Khanna, Dinesh , Tashkin, Donald , Martinez, Fernando , Chung, Lorinda , Hoffmann-Vold, Anna-Maria , Distler, Oliver , Johannson, Kerri A , Allanore, Yannick , Matteson, Eric L , Kawano-Dourado, Leticia , Pauling, John D , Seibold, James R , Volkmann, Elizabeth R , Oddis, Chester V , White, Eric S , Barratt, Shaney L , Bernstein, Elana J , Domsic, Robyn T , Dellaripa, Paul F , Conway, Richard , Rosas, Ivan , Hsu, Vivien , Ingegnoli, Francesca , Kahaleh, Bashar , Garcha, Puneet , Gupta, Nishant , Korsten, Peter , Strand, Vibeke , Steen, Virginia , Ovalles-Bonilla, Juan , Rodriguez-Pinto, Ignasi , Shenoy, Padmanabha D , Lescoat, Alain , Nagaraja, Vivek , Maher, Toby , Khanna, Dinesh , Assassi, Shervin , Mathai, Stephen C , Hoffmann‐Vold, Anna‐Maria , Distler, Oliver , Kawano-Dourado, Letícia , Oddis, Chester V. , Bernstein, Elana J. , Conway, Richard , Ingegnoli, Francesca , Gupta, Nishant , Korsten, Peter , Lewandoski, Andrew

Mayo Clinic

Rheumatology | September 29, 2022 | Volume: 62 | Issue: 5 | Pages: 1877-1886

10.1093/rheumatology/keac557 | PMID 36173318 Get It

Abstract Objectives To establish a framework by which experts define disease subsets in systemic sclerosis associated interstitial lung disease (SSc-ILD). Methods A conceptual framework for subclinical, clinical and progressive ILD was provided to 83 experts, asking them to use the framework and classify actual SSc-ILD patients. Each patient profile was designed to be classified by at least four experts in terms of severity and risk of progression at baseline; progression was based on 1-year follow-up data. A consensus was reached if ≥75% of experts agreed. Experts provided information on which items were important in determining classification. Results Forty-four experts (53%) completed the survey. Consensus was achieved on the dimensions of severity (75%, 60 of 80 profiles), risk of progression (71%, 57 of 80 profiles) and progressive ILD (60%, 24 of 40 profiles). For profiles achieving consensus, most were classified as clinical ILD (92%), low risk (54%) and stable (71%). Severity and disease progression overlapped in terms of framework items that were most influential in classifying patients (forced vital capacity, extent of lung involvement on high resolution chest CT [HRCT]); risk of progression was influenced primarily by disease duration. Conclusions Using our proposed conceptual framework, international experts were able to achieve a consensus on classifying SSc-ILD patients along the dimensions of disease severity, risk of progression and progression over time. Experts rely on similar items when classifying disease severity and progression: a combination of spirometry and gas exchange and quantitative HRCT.
Isolated Accessory Tricuspid Valve Leaflet in Asymptomatic Adult.
Inampudi, Jyothik V., Yirerong, Juliet , Sharma, Gyanendra K. , Gavlinksi, Sheena, Essa, Amr

Mayo Clinic

No container title available | September 29, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.166447089.98077256/v1 Get It

Accessory tricuspid valve (ATV) is a rare congenital anomaly that is often seen in complex congenital anomalies in children with very few reported cases in adults. We report a case of isolated ATV in an asymptomatic adult with no other congenital defects along with illustrative transesophageal echocardiographic 2D, 3D, high-resolution photo-realistic images.
Concordance of SARS-CoV-2 Antibody Results during a Period of Low Prevalence
Schlueter, David J., Garbett, Shawn , Ratsimbazafy, Francis, Karlson, Elizabeth W. , Cicek, Mine , Malin, Bradley , Ohno‐Machado, Lucila , Williams, Carolyn , Goldstein, David B. , Kouame, Aymone, Ramirez, Andrea H. , Schully, Sheri D. , Miller, Cheryl N , Pinto, Ligia A , Althoff, Keri N. , Anton‐Culver, Hoda , Chen, Qingxia , Thomsen, Isaac P. , Gebo, Kelly A

Mayo Clinic

mSphere | September 29, 2022 | Volume: 7 | Issue: 5 | Pages: No page available

10.1128/msphere.00257-22 | PMID 36173112 Get It

What is the agreement of commercial SARS-CoV-2 immunoglobulin G (IgG) assays during a time of low coronavirus disease 2019 (COVID-19) prevalence and no vaccine availability? Serological tests produced concordant results in a time of low SARS-CoV-2 prevalence and no vaccine availability, driven largely by the proportion of samples that were negative by two immunoassays. The CDC recommends two sequential tests for positivity for future pandemic preparedness.
Clinical application of ultra-high resolution compressed sensing time-of-flight MR angiography at 7T to detect small vessel pathology
Lakhani, Dhairya A. , Zhou, Xiangzhi , Tao, Shengzhen , Westerhold, Erin , Eidelman, Benjamin H., Middlebrooks, Erik H. , Westerhold, Erin M, Singh Sandhu, Sukhwinder Johnny, Middlebrooks, Erik H , Lakhani, Dhairya , Sandhu, Sukhwinder J.S.

Mayo Clinic

The Neuroradiology Journal | September 29, 2022 | Volume: 36 | Issue: 3 | Pages: 335-340

10.1177/19714009221129576 | PMID 36173305 Get It

3D time-of-flight (TOF) MR angiography (MRA) benefits from ultra-high-field MRI (≥7 T) due to improved contrast and increased signal-to-noise ratio. However, high-resolution TOF MRA at 7T usually requires longer acquisition times. In addition, relatively higher specific absorption rate (SAR) at 7T limits the choice of optimal pulse sequence parameters, especially if venous saturation is employed. Here, we illustrate the clinical application of ultra-high resolution cerebral 7T TOF MRA using compressed sensing in cases of artery of Percheron and lacunar infarcts, which showed superior resolution and exquisite details pertinent to the clinical diagnosis. The technical challenges associated with high-resolution 7T imaging were alleviated by optimization of sequence parameters and utilization of compressed sensing acceleration.